Living with Ulcerative Colitis (UC) is a challenging journey marked by unpredictable flare-ups involving abdominal pain, bloody diarrhea, and constant urgency. This chronic condition, which causes inflammation and ulcers in the lining of the large intestine, profoundly affects a person’s physical and emotional well-being, often dictating daily routines and limiting social activities. The goal of treatment is to control inflammation, alleviate symptoms, and achieve remission, or a prolonged period without active disease.

Treatment is essential to prevent complications such as malnutrition, severe bleeding, and damage to the intestinal wall. UC symptoms and treatment needs vary widely depending on the extent and severity of the inflammation, ranging from mild disease limited to the rectum to severe disease affecting the entire colon. Medication choices are based on the individual’s history and how their immune system responds to different drug classes (Crohn’s & Colitis Foundation, 2022).

Overview of treatment options for Ulcerative Colitis

The overall approach to treating Ulcerative Colitis follows a stepped strategy, moving from milder, localized therapies to stronger systemic medications. The main goals are twofold: to induce remission (stop a flare-up) and to maintain remission (prevent future flares).

Medications are the primary therapy for UC. They target the underlying, inappropriate immune response that causes inflammation. While diet and lifestyle changes are supportive, they do not replace the need for prescription drugs. Surgery, which involves removing the colon, is generally reserved as a last resort for severe cases that do not respond to medical therapy or for those facing serious complications. The majority of patients can effectively manage their condition long-term using medication.

Medications used for Ulcerative Colitis

Medication for UC involves several drug classes, often used in combination.

The first-line therapy for most mild to moderate cases is 5-aminosalicylates (5-ASAs), such as mesalamine and sulfasalazine. These drugs reduce inflammation directly in the lining of the colon and are crucial for maintaining remission. They can be taken orally or administered rectally (via enema or suppository) for localized disease.

For moderate to severe flare-ups, Corticosteroids (like prednisone or budesonide) are used short-term to quickly suppress inflammation. They are effective for inducing remission but are generally not used for long-term maintenance due to significant side effects.

If UC does not respond to 5-ASAs or is severe from the start, doctors turn to Immunomodulators (such as azathioprine or mercaptopurine) and Biologic Therapies. Biologics, including drugs that target TNF (tumor necrosis factor), often represent the most potent class of treatment. These newer drugs are used for moderate to severe disease when conventional therapy has failed.

How these medications work

The major drug classes for UC work by controlling the overactive immune system, which mistakenly attacks the lining of the colon.

5-ASAs deliver an anti-inflammatory compound directly to the colon wall, reducing irritation at the cellular level. They are effective because they work right where the inflammation is located. Corticosteroids are broad-spectrum immunosuppressants that quickly reduce immune activity throughout the body, providing rapid, powerful relief during acute flares.

Immunomodulators and Biologics act much more specifically. Immunomodulators broadly suppress the immune system’s production of inflammatory cells. Biologics are specially engineered proteins that block specific chemical messengers (like TNF-alpha or interleukins) that drive the inflammatory process. By stopping these targeted chemical signals, they prevent the chronic cycle of inflammation that damages the colon (National Institute of Diabetes and Digestive and Kidney Diseases, 2023).

Side effects and safety considerations

UC medications have potential side effects requiring regular follow-up. 5-ASAs commonly cause nausea, headache, or stomach upset. Potent corticosteroids can lead to insomnia, mood swings, weight gain, and higher infection risk with long-term use.

Immunomodulators and Biologics demand strict safety monitoring, including routine blood tests, as they suppress the immune system and increase the risk of serious infections. These drugs are generally contraindicated for patients with active infections or certain cancers. Seek immediate medical attention for severe, persistent fever, sudden vision changes, or signs of a serious allergic reaction.

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. American College of Gastroenterology. https://gi.org
  2. Crohn’s & Colitis Foundation. https://www.crohnscolitisfoundation.org
  3. Mayo Clinic. https://www.mayoclinic.org
  4. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov

Medications for Ulcerative Colitis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Ulcerative Colitis.

Found 26 Approved Drugs for Ulcerative Colitis

Infliximab

Brand Names
Zymfentra, Avsola, Inflectra, Remicade, Renflexis

Infliximab

Brand Names
Zymfentra, Avsola, Inflectra, Remicade, Renflexis
ZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 ) moderately to severely active Crohn’s disease following treatment with an infliximab products administered intraneously. ( 1 ) ZYMFENTRA is indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. moderately to severely active Crohn's disease following treatment with an infliximab product administered intravetnously.

Mesalamine

Brand Names
Pentasa, Canasa, Apriso, Lialda, sfRowasa Sulfite-Free, Rowasa

Mesalamine

Brand Names
Pentasa, Canasa, Apriso, Lialda, sfRowasa Sulfite-Free, Rowasa
Mesalamine delayed-release tablets are indicated for the: induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. Pediatric use information is approved for Takeda Pharmaceuticals U.S.A., Inc.'s LIALDA (mesalamine) delayed-release tablets. However, due to Takeda Pharmaceuticals U.S.A., Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. Mesalamine delayed-release tablets are an aminosalicylate indicated for the: induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. ( 1 )

Entyvio

Generic Name
Vedolizumab

Entyvio

Generic Name
Vedolizumab
ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD). ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). ( 1 ) moderately to severely active Crohn's disease (CD). ( 1 )

Sulfasalazine

Brand Names
Azulfidine, Azulfidine EN-tabs

Sulfasalazine

Brand Names
Azulfidine, Azulfidine EN-tabs
Sulfasalazine delayed release tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; b) for the prolongation of the remission period between acute attacks of ulcerative colitis; c) in the treatment of patients with rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs (e.g., an insufficient therapeutic response to, or intolerance of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs); and d) in the treatment of pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs. Sulfasalazine delayed release tablets are particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. In patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. Unlike anti-inflammatory drugs, sulfasalazine delayed release tablets do not produce an immediate response. Concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of sulfasalazine delayed release tablets is apparent.

Adalimumab

Brand Names
Adalimumab-aacf, Humira

Adalimumab

Brand Names
Adalimumab-aacf, Humira
HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
Showing 1-5 of 26
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances